FTH · Faeth Therapeutics Inc. Common Stock
View on chartInsiders & Stakes
| Anand Kiran Parikh President and CEO | ▲ Buy | Option Exercise | 817,699 Shares held | 6/22/2026 | View profile |
| MILLENNIUM MANAGEMENT LLC 10% Owner | ▼ Sell | Open Market | 133,986 Shares held | 4/7/2026 | View profile |
| Cambrian BioPharma Inc 10% Owner | ▼ Sell | Open Market | 130,142 Shares held | 6/1/2026 | View profile |
| James Peyer Director | ▼ Sell | Open Market | 130,142 Shares held | 6/1/2026 | View profile |
| John Celebi President and CEO | ▼ Sell | Tax Withholding | 105,862 Shares held | 2/19/2025 | View profile |
| Colgan Erin Chief Financial Officer | ▼ Sell | Tax Withholding | 67,462 Shares held | 2/15/2024 | View profile |
| van der Horst Edward Chief Scientific Officer | ▼ Sell | Tax Withholding | 59,794 Shares held | 2/19/2025 | View profile |
| Brian C. Stephenson See Remarks | ▲ Buy | Open Market | 46,688 Shares held | 7/1/2026 | View profile |
| Stephen M. Hahn | ▼ Sell | Other | 44,763 Shares held | 6/15/2026 | View profile |
| Gallagher Patrick Stephen Chief Business Officer | ▲ Buy | Grant | 43,515 Shares held | 2/15/2023 | View profile |
| Holmen Bob Director | ▲ Buy | Grant | 25,598 Shares held | 7/10/2023 | View profile |
| RINGO WILLIAM R Director | ▲ Buy | Grant | 23,399 Shares held | 7/10/2023 | View profile |
| Pierce Robert Hamilton Chief R&D Officer | ▲ Buy | Grant | 21,000 Shares held | 2/15/2022 | View profile |
| Thomas G. Ricks Director | ▲ Buy | Grant | 8,932 Shares held | 7/10/2023 | View profile |
| Broder Samuel Director | ▲ Buy | Grant | 8,932 Shares held | 7/10/2023 | View profile |
| Humer Kristian Director | ▲ Buy | Grant | 8,932 Shares held | 7/10/2023 | View profile |
| English Jessie Director | ▲ Buy | Grant | 8,932 Shares held | 7/10/2023 | View profile |
| Vojta Deneen Director | ▲ Buy | Grant | 8,932 Shares held | 7/10/2023 | View profile |
| Apeiron Investment Group Ltd. 10% Owner | ▼ Sell | Open Market | 0 Shares held | 6/1/2023 | View profile |
Transaction History
| Brian C. Stephenson | ▲ Buy | Open Market | 4,400 | $103K | 7/1/2026 |
| Brian C. Stephenson | ▲ Buy | Open Market | 600 | $15K | 7/1/2026 |
| Brian C. Stephenson | ▲ Buy | Open Market | 1,910 | $44K | 6/30/2026 |
| Brian C. Stephenson | ▲ Buy | Open Market | 1,638 | $39K | 6/30/2026 |
| Brian C. Stephenson | ▲ Buy | Open Market | 4,255 | $106K | 6/30/2026 |
| Brian C. Stephenson | ▲ Buy | Open Market | 831 | $19K | 6/29/2026 |
| Brian C. Stephenson | ▲ Buy | Open Market | 1,358 | $35K | 6/26/2026 |
| Brian C. Stephenson | ▲ Buy | Open Market | 580 | $14K | 6/26/2026 |
| Brian C. Stephenson | ▲ Buy | Open Market | 4,212 | $105K | 6/26/2026 |
| Brian C. Stephenson | ▲ Buy | Open Market | 100 | $3K | 6/26/2026 |
| Brian C. Stephenson | ▲ Buy | Open Market | 3,000 | $78K | 6/24/2026 |
| Brian C. Stephenson | ▲ Buy | Open Market | 3,400 | $92K | 6/24/2026 |
| Brian C. Stephenson | ▲ Buy | Open Market | 100 | $3K | 6/24/2026 |
| Brian C. Stephenson | ▲ Buy | Open Market | 2,891 | $73K | 6/24/2026 |
| Brian C. Stephenson | ▲ Buy | Open Market | 6,836 | $165K | 6/23/2026 |
| Brian C. Stephenson | ▲ Buy | Open Market | 1,969 | $49K | 6/23/2026 |
| Brian C. Stephenson | ▲ Buy | Open Market | 425 | $11K | 6/23/2026 |
| Brian C. Stephenson | ▲ Buy | Open Market | 1,797 | $36K | 6/22/2026 |
| Brian C. Stephenson | ▲ Buy | Open Market | 1,118 | $23K | 6/22/2026 |
| Brian C. Stephenson | ▲ Buy | Open Market | 1,583 | $35K | 6/22/2026 |
| Brian C. Stephenson | ▲ Buy | Open Market | 3,329 | $77K | 6/22/2026 |
| Brian C. Stephenson | ▲ Buy | Open Market | 356 | $9K | 6/22/2026 |
| Anand Kiran Parikh | ▲ Buy | Open Market | 2,806 | $55K | 6/22/2026 |
| Anand Kiran Parikh | ▲ Buy | Option Exercise | 45,252 | $52K | 6/22/2026 |
| Anand Kiran Parikh | ▲ Buy | Option Exercise | 8,213 | $10K | 6/22/2026 |
| Stephen M. Hahn | ▼ Sell | Other | 44,763 | — | 6/15/2026 |
| Anand Kiran Parikh | ▼ Sell | Other | 761,428 | — | 6/15/2026 |
| Cambrian BioPharma Inc | ▼ Sell | Open Market | 24,524 | $490K | 6/1/2026 |
| Cambrian BioPharma Inc | ▼ Sell | Open Market | 476 | $10K | 6/1/2026 |
| James Peyer | ▼ Sell | Open Market | 24,524 | $490K | 6/1/2026 |
| James Peyer | ▼ Sell | Open Market | 476 | $10K | 6/1/2026 |
| MILLENNIUM MANAGEMENT LLC | ▼ Sell | Open Market | 300 | $10K | 4/7/2026 |
| MILLENNIUM MANAGEMENT LLC | ▲ Buy | Open Market | 1,108 | $37K | 4/7/2026 |
| MILLENNIUM MANAGEMENT LLC | ▼ Sell | Open Market | 2,115 | $61K | 4/7/2026 |
| MILLENNIUM MANAGEMENT LLC | ▼ Sell | Open Market | 205 | $6K | 4/7/2026 |
| MILLENNIUM MANAGEMENT LLC | ▼ Sell | Open Market | 4,423 | $139K | 4/7/2026 |
| MILLENNIUM MANAGEMENT LLC | ▼ Sell | Open Market | 1,108 | $37K | 4/7/2026 |
| MILLENNIUM MANAGEMENT LLC | ▲ Buy | Open Market | 1,104 | $34K | 4/6/2026 |
| MILLENNIUM MANAGEMENT LLC | ▼ Sell | Open Market | 1,214 | $38K | 4/6/2026 |
| MILLENNIUM MANAGEMENT LLC | ▼ Sell | Open Market | 45 | $1K | 4/6/2026 |
| MILLENNIUM MANAGEMENT LLC | ▲ Buy | Open Market | 26 | $870 | 4/2/2026 |
| MILLENNIUM MANAGEMENT LLC | ▲ Buy | Open Market | 1,276 | $44K | 4/2/2026 |
| MILLENNIUM MANAGEMENT LLC | ▲ Buy | Open Market | 701 | $25K | 4/2/2026 |
| MILLENNIUM MANAGEMENT LLC | ▼ Sell | Open Market | 3,099 | $96K | 4/2/2026 |
| MILLENNIUM MANAGEMENT LLC | ▼ Sell | Open Market | 1,265 | $40K | 4/2/2026 |
| MILLENNIUM MANAGEMENT LLC | ▼ Sell | Open Market | 1,794 | $58K | 4/2/2026 |
| MILLENNIUM MANAGEMENT LLC | ▼ Sell | Open Market | 374 | $12K | 4/2/2026 |
| MILLENNIUM MANAGEMENT LLC | ▼ Sell | Open Market | 1,134 | $39K | 4/2/2026 |
| MILLENNIUM MANAGEMENT LLC | ▲ Buy | Open Market | 1,161 | $37K | 4/1/2026 |
| MILLENNIUM MANAGEMENT LLC | ▲ Buy | Open Market | 1,613 | $56K | 4/1/2026 |
| MILLENNIUM MANAGEMENT LLC | ▲ Buy | Open Market | 3,401 | $121K | 4/1/2026 |
| MILLENNIUM MANAGEMENT LLC | ▼ Sell | Open Market | 1,104 | $35K | 4/1/2026 |
| MILLENNIUM MANAGEMENT LLC | ▼ Sell | Open Market | 46 | $2K | 4/1/2026 |
| MILLENNIUM MANAGEMENT LLC | ▲ Buy | Open Market | 616 | $15K | 3/31/2026 |
| MILLENNIUM MANAGEMENT LLC | ▲ Buy | Open Market | 1,770 | $45K | 3/31/2026 |
| MILLENNIUM MANAGEMENT LLC | ▲ Buy | Open Market | 1,048 | $28K | 3/31/2026 |
| MILLENNIUM MANAGEMENT LLC | ▲ Buy | Open Market | 17 | $472 | 3/31/2026 |
| MILLENNIUM MANAGEMENT LLC | ▲ Buy | Open Market | 186 | $6K | 3/31/2026 |
| MILLENNIUM MANAGEMENT LLC | ▲ Buy | Open Market | 1,957 | $62K | 3/31/2026 |
| MILLENNIUM MANAGEMENT LLC | ▲ Buy | Open Market | 411 | $13K | 3/31/2026 |
| MILLENNIUM MANAGEMENT LLC | ▼ Sell | Open Market | 191 | $5K | 3/31/2026 |
| MILLENNIUM MANAGEMENT LLC | ▼ Sell | Open Market | 1,251 | $31K | 3/31/2026 |
| MILLENNIUM MANAGEMENT LLC | ▼ Sell | Open Market | 57 | $2K | 3/31/2026 |
| MILLENNIUM MANAGEMENT LLC | ▼ Sell | Open Market | 5 | $142 | 3/31/2026 |
| MILLENNIUM MANAGEMENT LLC | ▼ Sell | Open Market | 87 | $3K | 3/31/2026 |
| MILLENNIUM MANAGEMENT LLC | ▲ Buy | Open Market | 2,992 | $75K | 3/30/2026 |
| MILLENNIUM MANAGEMENT LLC | ▲ Buy | Open Market | 4,995 | $130K | 3/30/2026 |
| MILLENNIUM MANAGEMENT LLC | ▲ Buy | Open Market | 1,176 | $31K | 3/30/2026 |
| MILLENNIUM MANAGEMENT LLC | ▲ Buy | Open Market | 370 | $10K | 3/30/2026 |
| MILLENNIUM MANAGEMENT LLC | ▼ Sell | Open Market | 518 | $13K | 3/30/2026 |
| MILLENNIUM MANAGEMENT LLC | ▼ Sell | Open Market | 370 | $10K | 3/30/2026 |
| MILLENNIUM MANAGEMENT LLC | ▲ Buy | Open Market | 10,643 | $280K | 3/27/2026 |
| MILLENNIUM MANAGEMENT LLC | ▲ Buy | Open Market | 4,384 | $120K | 3/27/2026 |
| MILLENNIUM MANAGEMENT LLC | ▲ Buy | Open Market | 294 | $8K | 3/27/2026 |
| MILLENNIUM MANAGEMENT LLC | ▼ Sell | Open Market | 469 | $13K | 3/27/2026 |
| MILLENNIUM MANAGEMENT LLC | ▼ Sell | Open Market | 36 | $985 | 3/27/2026 |
| MILLENNIUM MANAGEMENT LLC | ▲ Buy | Open Market | 778 | $21K | 3/26/2026 |
| MILLENNIUM MANAGEMENT LLC | ▲ Buy | Open Market | 1,327 | $37K | 3/26/2026 |
| MILLENNIUM MANAGEMENT LLC | ▲ Buy | Open Market | 2,601 | $75K | 3/26/2026 |
| MILLENNIUM MANAGEMENT LLC | ▲ Buy | Open Market | 1,025 | $31K | 3/26/2026 |
| MILLENNIUM MANAGEMENT LLC | ▼ Sell | Open Market | 583 | $16K | 3/26/2026 |
| MILLENNIUM MANAGEMENT LLC | ▼ Sell | Open Market | 1,274 | $37K | 3/26/2026 |
| Cambrian BioPharma Inc | ▼ Sell | Open Market | 2,666 | $21K | 12/9/2025 |
| Cambrian BioPharma Inc | ▲ Buy | Option Exercise | 395 | $3K | 12/9/2025 |
| Cambrian BioPharma Inc | ▼ Sell | Open Market | 3,105 | $27K | 12/9/2025 |
| Cambrian BioPharma Inc | ▼ Sell | Open Market | 395 | $3K | 12/9/2025 |
| Cambrian BioPharma Inc | ▼ Sell | Open Market | 446 | $4K | 12/9/2025 |
| James Peyer | ▼ Sell | Open Market | 2,666 | $21K | 12/9/2025 |
| James Peyer | ▲ Buy | Option Exercise | 395 | $3K | 12/9/2025 |
| James Peyer | ▼ Sell | Open Market | 395 | $3K | 12/9/2025 |
| James Peyer | ▼ Sell | Open Market | 446 | $4K | 12/9/2025 |
| James Peyer | ▼ Sell | Open Market | 3,105 | $27K | 12/8/2025 |
| Cambrian BioPharma Inc | ▼ Sell | Open Market | 14,508 | $165K | 12/5/2025 |
| Cambrian BioPharma Inc | ▼ Sell | Open Market | 1,745 | $21K | 12/5/2025 |
| Cambrian BioPharma Inc | ▼ Sell | Open Market | 42 | $553 | 12/5/2025 |
| James Peyer | ▼ Sell | Open Market | 14,508 | $165K | 12/5/2025 |
| James Peyer | ▼ Sell | Open Market | 1,745 | $21K | 12/5/2025 |
| James Peyer | ▼ Sell | Open Market | 42 | $553 | 12/5/2025 |
| Cambrian BioPharma Inc | ▼ Sell | Open Market | 5,000 | $45K | 12/4/2025 |
| James Peyer | ▼ Sell | Open Market | 5,000 | $45K | 12/4/2025 |
| John Celebi | ▼ Sell | Tax Withholding | 5,558 | $3K | 2/19/2025 |
| van der Horst Edward | ▼ Sell | Tax Withholding | 2,276 | $1K | 2/19/2025 |
| van der Horst Edward | ▼ Sell | Tax Withholding | 2,843 | $2K | 2/15/2024 |
| John Celebi | ▼ Sell | Tax Withholding | 5,891 | $5K | 2/15/2024 |
| Colgan Erin | ▼ Sell | Tax Withholding | 3,627 | $3K | 2/15/2024 |
| John Celebi | ▲ Buy | Open Market | 500 | $425 | 9/11/2023 |
| James Peyer | ▼ Sell | Other | 1,587,302 | $2.0M | 7/31/2023 |
| Cambrian BioPharma Inc | ▼ Sell | Other | 1,587,302 | $2.0M | 7/31/2023 |
| Broder Samuel | ▲ Buy | Grant | 4,466 | $0 | 7/10/2023 |
| Holmen Bob | ▲ Buy | Grant | 4,466 | $0 | 7/10/2023 |
| James Peyer | ▲ Buy | Grant | 4,466 | $0 | 7/10/2023 |
| English Jessie | ▲ Buy | Grant | 4,466 | $0 | 7/10/2023 |
| Thomas G. Ricks | ▲ Buy | Grant | 4,466 | $0 | 7/10/2023 |
| RINGO WILLIAM R | ▲ Buy | Grant | 4,466 | $0 | 7/10/2023 |
| Humer Kristian | ▲ Buy | Grant | 4,466 | $0 | 7/10/2023 |
| Cambrian BioPharma Inc | ▲ Buy | Grant | 4,466 | $0 | 7/10/2023 |
| Vojta Deneen | ▲ Buy | Grant | 4,466 | $0 | 7/10/2023 |
| Apeiron Investment Group Ltd. | ▼ Sell | Open Market | 955,738 | $1.5M | 6/1/2023 |
| Apeiron Investment Group Ltd. | ▼ Sell | Open Market | 2,485,923 | $3.9M | 6/1/2023 |
| Apeiron Investment Group Ltd. | ▲ Buy | Open Market | 1,100 | $2K | 2/23/2023 |
| Apeiron Investment Group Ltd. | ▲ Buy | Open Market | 1,100 | $2K | 2/23/2023 |
| van der Horst Edward | ▼ Sell | Tax Withholding | 9,525 | $14K | 2/15/2023 |
| Colgan Erin | ▼ Sell | Tax Withholding | 10,943 | $16K | 2/15/2023 |
| John Celebi | ▼ Sell | Tax Withholding | 20,492 | $31K | 2/15/2023 |
| Colgan Erin | ▲ Buy | Grant | 21,300 | $0 | 2/15/2023 |
| Gallagher Patrick Stephen | ▼ Sell | Tax Withholding | 9,383 | $14K | 2/15/2023 |
| van der Horst Edward | ▲ Buy | Grant | 17,700 | $0 | 2/15/2023 |
| Gallagher Patrick Stephen | ▲ Buy | Grant | 29,313 | $0 | 2/15/2023 |
| John Celebi | ▲ Buy | Grant | 21,300 | $0 | 2/15/2023 |
| van der Horst Edward | ▲ Buy | Grant | 23,565 | $0 | 2/15/2023 |
| John Celebi | ▲ Buy | Grant | 51,893 | $0 | 2/15/2023 |
| Gallagher Patrick Stephen | ▲ Buy | Grant | 14,200 | $0 | 2/15/2023 |
| Colgan Erin | ▲ Buy | Grant | 30,046 | $0 | 2/15/2023 |
| Cambrian BioPharma Inc | ▲ Buy | Grant | 4,466 | $0 | 6/10/2022 |
| Thomas G. Ricks | ▲ Buy | Grant | 4,466 | $0 | 6/10/2022 |
| Humer Kristian | ▲ Buy | Grant | 4,466 | $0 | 6/10/2022 |
| Holmen Bob | ▲ Buy | Grant | 4,466 | $0 | 6/10/2022 |
| English Jessie | ▲ Buy | Grant | 4,466 | $0 | 6/10/2022 |
| Vojta Deneen | ▲ Buy | Grant | 4,466 | $0 | 6/10/2022 |
| Broder Samuel | ▲ Buy | Grant | 4,466 | $0 | 6/10/2022 |
| James Peyer | ▲ Buy | Grant | 4,466 | $0 | 6/10/2022 |
| RINGO WILLIAM R | ▲ Buy | Grant | 10,000 | $0 | 3/8/2022 |
| RINGO WILLIAM R | ▲ Buy | Grant | 8,933 | $0 | 3/8/2022 |
| Cambrian BioPharma Inc | ▲ Buy | Open Market | 1,203 | $4K | 3/2/2022 |
| James Peyer | ▲ Buy | Open Market | 1,203 | $4K | 3/2/2022 |
| James Peyer | ▲ Buy | Open Market | 2,458 | $9K | 3/1/2022 |
| Cambrian BioPharma Inc | ▲ Buy | Open Market | 2,458 | $9K | 3/1/2022 |
| James Peyer | ▲ Buy | Open Market | 42 | $151 | 2/28/2022 |
| Cambrian BioPharma Inc | ▲ Buy | Open Market | 42 | $151 | 2/28/2022 |
| James Peyer | ▲ Buy | Open Market | 2,500 | $9K | 2/25/2022 |
| Cambrian BioPharma Inc | ▲ Buy | Open Market | 2,500 | $9K | 2/25/2022 |
| Cambrian BioPharma Inc | ▲ Buy | Open Market | 15,000 | $54K | 2/24/2022 |
| James Peyer | ▲ Buy | Open Market | 15,000 | $54K | 2/24/2022 |
| Cambrian BioPharma Inc | ▲ Buy | Open Market | 2,500 | $10K | 2/23/2022 |
| James Peyer | ▲ Buy | Open Market | 2,500 | $10K | 2/23/2022 |
| James Peyer | ▲ Buy | Open Market | 15,000 | $60K | 2/18/2022 |
| Cambrian BioPharma Inc | ▲ Buy | Open Market | 15,000 | $60K | 2/18/2022 |
| James Peyer | ▲ Buy | Open Market | 4,949 | $21K | 2/17/2022 |
| Cambrian BioPharma Inc | ▲ Buy | Open Market | 4,949 | $21K | 2/17/2022 |
| Cambrian BioPharma Inc | ▲ Buy | Open Market | 2,551 | $11K | 2/16/2022 |
| James Peyer | ▲ Buy | Open Market | 2,551 | $11K | 2/16/2022 |
| Pierce Robert Hamilton | ▲ Buy | Grant | 21,000 | $0 | 2/15/2022 |
| Colgan Erin | ▲ Buy | Grant | 21,000 | $0 | 2/15/2022 |
| John Celebi | ▲ Buy | Grant | 53,900 | $0 | 2/15/2022 |
| Cambrian BioPharma Inc | ▲ Buy | Open Market | 10,000 | $42K | 2/14/2022 |
| James Peyer | ▲ Buy | Open Market | 10,000 | $42K | 2/14/2022 |
| James Peyer | ▲ Buy | Open Market | 12,500 | $55K | 2/11/2022 |
| Cambrian BioPharma Inc | ▲ Buy | Open Market | 12,500 | $55K | 2/11/2022 |
| James Peyer | ▲ Buy | Open Market | 5,000 | $23K | 2/10/2022 |
| Cambrian BioPharma Inc | ▲ Buy | Open Market | 5,000 | $23K | 2/10/2022 |
| Cambrian BioPharma Inc | ▲ Buy | Open Market | 10,000 | $43K | 2/8/2022 |
| James Peyer | ▲ Buy | Open Market | 10,000 | $43K | 2/8/2022 |
| Cambrian BioPharma Inc | ▲ Buy | Open Market | 2,500 | $11K | 2/4/2022 |
| James Peyer | ▲ Buy | Open Market | 2,500 | $11K | 2/4/2022 |
| Cambrian BioPharma Inc | ▲ Buy | Open Market | 17,500 | $81K | 2/3/2022 |
| James Peyer | ▲ Buy | Open Market | 17,500 | $81K | 2/3/2022 |
| Cambrian BioPharma Inc | ▲ Buy | Open Market | 8,900 | $38K | 1/28/2022 |
| James Peyer | ▲ Buy | Open Market | 8,900 | $38K | 1/28/2022 |
| Cambrian BioPharma Inc | ▲ Buy | Open Market | 6,100 | $26K | 1/27/2022 |
| James Peyer | ▲ Buy | Open Market | 6,100 | $26K | 1/27/2022 |
| James Peyer | ▲ Buy | Open Market | 29,900 | $138K | 1/26/2022 |
| Cambrian BioPharma Inc | ▲ Buy | Open Market | 29,900 | $138K | 1/26/2022 |
| James Peyer | ▲ Buy | Open Market | 20,100 | $98K | 1/25/2022 |
| Cambrian BioPharma Inc | ▲ Buy | Open Market | 20,100 | $98K | 1/25/2022 |
| James Peyer | ▲ Buy | Open Market | 22,707 | $106K | 1/24/2022 |
| Cambrian BioPharma Inc | ▲ Buy | Open Market | 22,707 | $106K | 1/24/2022 |
| James Peyer | ▲ Buy | Open Market | 24,703 | $122K | 1/21/2022 |
| Cambrian BioPharma Inc | ▲ Buy | Open Market | 24,703 | $122K | 1/21/2022 |
| James Peyer | ▲ Buy | Open Market | 20,000 | $103K | 1/20/2022 |
| Cambrian BioPharma Inc | ▲ Buy | Open Market | 20,000 | $103K | 1/20/2022 |
| James Peyer | ▲ Buy | Open Market | 10,244 | $51K | 1/19/2022 |
| Cambrian BioPharma Inc | ▲ Buy | Open Market | 10,244 | $51K | 1/19/2022 |
| James Peyer | ▲ Buy | Open Market | 10,000 | $51K | 1/18/2022 |
| Cambrian BioPharma Inc | ▲ Buy | Open Market | 10,000 | $51K | 1/18/2022 |
| James Peyer | ▲ Buy | Open Market | 6,219 | $31K | 1/14/2022 |
| Cambrian BioPharma Inc | ▲ Buy | Open Market | 6,219 | $31K | 1/14/2022 |
| James Peyer | ▲ Buy | Open Market | 19,953 | $102K | 1/13/2022 |
| Cambrian BioPharma Inc | ▲ Buy | Open Market | 19,953 | $102K | 1/13/2022 |
| James Peyer | ▲ Buy | Open Market | 9,202 | $48K | 1/12/2022 |
| Cambrian BioPharma Inc | ▲ Buy | Open Market | 9,202 | $48K | 1/12/2022 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
William Blair Begins Coverage of Faeth Therapeutics (FTH)
William Blair has started coverage of Faeth Therapeutics and issued an Outperform rating. The move may increase analyst attention and could influence market perception. The stock is currently trading below its 52‑week low and has a low RSI, indicating it is in a downtrend.
William Blair Begins Coverage of Faeth Therapeutics (FTH). William Blair has started coverage of Faeth Therapeutics and issued an Outperform rating. The move may increase analyst attention and could influence market perception. The stock is currently trading below its 52‑week low and has a low RSI, indicating it is in a downtrend.